TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01725724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Description: Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic blood transfusion
Description: Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
Study: NCT03928249

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eriocitrin
Description: A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eriocitrin
Description: A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.
Study: NCT02194699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tralokinumab
Description: Tralokinumab subcutaneous injection
Study: NCT03994315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis EVC001
Description: Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-N-tetraose (LNT)
Description: LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacto-N-tetraose (LNT)
Description: LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
Study: NCT00724906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123 I - ALTROPANE®
Description: 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123 I - ALTROPANE®
Description: 8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
Study: NCT02303821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Study: NCT01670617

Intervention type: OTHER
Group type: OTHER
Intervention: Particulated Juvenile Articular Cartilage
Description: Treatment of articular cartilage defects up to 7.5 cm2
Study: NCT00970827

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic postconditioning
Description: Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic postconditioning
Description: Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: remote ischemic postconditioning
Description: Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
Study: NCT03536611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
Study: NCT01998841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab will be administered as per the schedule specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the treatment arm.
Study: NCT01056289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg
Description: DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
Description: DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
Study: NCT04604340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial access for neuroangiography
Description: The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial access for neuroangiography
Description: The choice of right vs left radial artery approach would be determined by the vessels that require the highest quality of imaging (e.g. if the left vertebral artery is key to diagnosis, a left radial approach would be chosen, otherwise a right radial approach would be likely most appropriate) - this decision is at the discretion of the interventionist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfemoral access for neuroangiography
Description: By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfemoral access for neuroangiography
Description: By convention, femoral access will be obtained on the right side, unless there is overlying disease or vessel abnormality detected by ultrasound/Doppler, as is usual clinical practice.
Study: NCT04952818

Intervention type: DIAGNOSTIC_TEST
Intervention: RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)
Description: Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).

Intervention type: DIAGNOSTIC_TEST
Intervention: RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)
Description: Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).
Study: NCT01653717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 by vein on Days -5 to Day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/kg by vein on Days -5 to -3.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell Infusion
Description: Beginning dose of genetically modified cells is \> 5x10\^7/m2 but less than or equal to 5 x10\^8/m2 infused on Day 0.
Study: NCT03544944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJP-008-1
Description: Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJP-008-2
Description: Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolprep powder
Description: Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
Study: NCT05937737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Diet Modification
Description: A 12-week dietary intervention model was prescribed to the patients in accordance with their needs.
Study: NCT01476514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
Study: NCT03619265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prickly pear juice
Description: 3 ounces daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pear-flavored juice
Description: 3 ounces daily for 8 weeks.
Study: NCT02128672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator Lead Placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator Lead Placement
Study: NCT01044121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mattress Firmness
Description: Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
Study: NCT01708551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT01027195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar Radiofrequency (Aquamantys 6.0)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Bovie Electrocautery
Study: NCT01098630

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Patients' medical record information is collected and staff complete the treatment review form

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01650584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISTA Tears
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Sterile ophthalmic solution
Study: NCT05014841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Tasks
Description: Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
Study: NCT01402635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: point-of-care chemistry test(POCT) (Piccolo)
Description: comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: point-of-care chemistry test(POCT) (Piccolo)
Description: comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
Study: NCT04305353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary (blank journal) plus PTSD psycho-education
Description: A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PTSD psycho-education alone
Description: We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015.

Intervention type: OTHER
Group type: OTHER
Intervention: PTSD psycho-education alone
Description: We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015.
Study: NCT04075409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil will be administered in predefined dosages.
Study: NCT02318290

Intervention type: DRUG
Intervention: Opiates
Description: Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
Study: NCT02580383

Intervention type: PROCEDURE
Intervention: Radiofrequency neurotomy of lumbar medial branch
Description: In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.

Intervention type: PROCEDURE
Intervention: Radiofrequency neurotomy of lumbar medial branch
Description: In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.

Intervention type: PROCEDURE
Intervention: Radiofrequency neurotomy of lumbar medial branch
Description: In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
Study: NCT01243528

Intervention type: OTHER
Intervention: Laboratory values
Description: Laboratory values which represent nutritional status
Study: NCT01180608

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Spectroscopy
Description: During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MR Spectroscopy
Description: During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~* gamma-aminobutyric acid (GABA)~* glutamate (Glu)~* glutamine (Gln)~* N-acetylaspartate (NAA)~* Choline-containing compounds (Cho)~* Creatine plus phophocreatine (total creatine: Cr)~* Myo-inositiol (Ins)~* Choline (Cho)~* Glucose (Glc)~* Lactate (Lac)
Study: NCT04590690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Special diet
Description: The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Special diet
Description: The research clinic will provide subjects with a special diet for six days. After six days of isocaloric sodium, calcium and fluid intake, the study team will analyze three sequential 24-hour urine compositions including supersaturation of calcium oxalate, calcium, and urine volume, as well as stool collections. We will also evaluate components of 24-hour urine composition, specifically supersaturation, and the microbial contributions to urinary composition in 72-hour stool samples simultaneously collected using shot-gun metagenomic sequencing in men and women 1 year after surgery.
Study: NCT01256021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
Study: NCT02426151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEPO-A
Description: BEPO-A (Bioreactor manufacturing process)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REPO-A
Description: REPO-A (Roller bottle manufacturing process)